Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Blank Check IPOs (SPACS) -- Ignore unavailable to you. Want to Upgrade?

To: chuckmicro who wrote (924)	5/11/2007 1:06:44 AM
From: chuckmicro	Read Replies (2) \| Respond to of 3862

HAPNW -A Warrant Opportunity The deadline for shareholder approval to acquire InfuSystem, Inc. has been extended from April 30 to June 27, 2007. Also extended is the date of the $1 million breakup penalty if the acquisition is not approved by the June 27th date. Of particular interest in the 5/4/07 form 8-K, is the purchase on April 12, 2007 of 447,143 warrants at $0.70 each (cost $313,000) by the Board Chairman Sean McDevitt. This purchase was direct from HAPN while the warrants were selling for $0.22 on the open market. Previously, on 12/28/06, Mr. McDevitt bought 624,000 warrants at $0.70 direct from the company (a $437,000 investment) when they could have been purchased on the open market at .25 - .30. Mr. McDevitt is one of the two people who have provided a $3 million letter of credit to I-Flow as a guarantee that the acquisition will go through. Also, according to the 3/30/07 form 10-K, Mr. McDevitt is one of two people who have agreed to ensure that shareholders will receive the full amount in the trust fund if no acquisition is made by HAPN. The warrants are now selling in the .21 -22 range. If the acquisition goes through, they should be selling in the .60 - .90 range. If the acquisition does not go through, the warrants will probably become worthless. Mr. McDevitt has shown he is a believer and has consistently put his money on a successful acquisition. Here is some biographical information on Sean McDevitt: He is currently a Managing Director at FTN Midwest Securities Corp. In 1999 he co-founded Alterity Partners, a boutique investment bank providing capital markets and merger and acquisition advisory services to high growth companies. Alterity Partners was acquired by FTN Midwest Securities Corp in September 2004. Mr. McDevitt was formerly a senior investment banker at Goldman Sachs & Co., where he led deal teams in a variety of technology and healthcare/biopharmaceutical transactions, including mergers and acquisitions, divestitures and IPO's. Mr. McDevitt worked in sales and marketing at Pfizer. He was a Captain in the U.S. Army Rangers and was decorated for combat in the Panama invasion. He is a member of the Council on Foreign Relations. He received his B.S. in Computer Science and Electrical Engineering from the U.S. Military Academy at West Point and an M.B.A. from Harvard Business School.

To: chuckmicro who wrote (924)	5/18/2007 9:36:28 AM
From: lazarre	Respond to of 3862

chuck, while reading thru the PR's beginning last February, I singled out this paragraph from their Q earnings PR: "IV Infusion Therapy revenue increased 31% to $7,862,000 for the fourth quarter of 2006 from $5,989,000 in the prior year quarter, the result of continued strong growth in both domestic and international markets. "We were surprised by the strength of our IV Infusion Therapy business in the fourth quarter, and expect revenue growth to return to a more modest pace beginning in the first quarter of 2007," Earhart said." Is this the unit Hapn will be acquiring if the buy goes through? I'm not worried about the more modest pace, as Earhart states---IMO, the demographics are still compelling. I also thought, and I might have confused HAPN, with another blank check, HAPN was going to get a NAZ small cap listing. tia, lazarre